SavedAdd your journal

Journals / MN Oftalmoloji / 2017 / Cilt: 24 - Sayı: 1

Research of Tissue Inhibitor of Matrix Metalloproteinase-1, Matrix Metalloproteinase-9, Connective Tissue Growth Factor, Vascular Endothelial Growth Factor Levels in Blood in the Eyes of Patients with and Without Pseudoexfoliation Syndrome

Serumda Matriks Metalloproteinaz Doku İnhibitörleri-1, Matriks Metalloproteinaz-9, Bağ Dokusu Büyüme Faktörü ve Vasküler Endotelyal Büyüme Faktörü Düzeylerinin Psödoeksfolyasyon Sendromlu Hastalarda Araştırılması

Hande Hüsniye TELEK
Miraç Ali YAVRUOĞLU
YAPRAK ARZU ÖZDEMİR
Pages
25–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It might be foreseen that development of preventive treatments in the future by regulation of interactions between matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and connective tissue growth factor will inhibit or slow down the progression of pseudoexfoliation syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study we aimed to determine if serum levels of tissue inhibitor of metalloproteinase-1, matrix metalloproteinase-9, connective tissue growth factor and vascular endothelial growth factor differred between patients with pseudoexfoliation syndrome and without pseudoexfoliation syndrome.
📊
Key Findings & Data:Material and Method: Pseudoexfoliation syndrome group 50 eyes, control group 48 eyes were included in the study.
💡
Conclusion & Impact:It might be foreseen that development of preventive treatments in the future by regulation of interactions between matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and connective tissue growth factor will inhibit or slow down the progression of pseudoexfoliation syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this study we aimed to determine if serum levels of tissue inhibitor of metalloproteinase-1, matrix metalloproteinase-9, connective tissue growth factor and vascular endothelial growth factor differred between patients with pseudoexfoliation syndrome and without pseudoexfoliation syndrome. Material and Method: Pseudoexfoliation syndrome group 50 eyes, control group 48 eyes were included in the study. Blood specimens (5 mL) were collected from the forearm. Serum specimens obtained after centrifugation of blood samples were stored in deep freezer until analysis. Tissue inhibitor of metalloproteinase-1, matrix metalloproteinase-9, connective tissue growth factor and vascular endothelial growth factor levels were determined in serum samples using specific enzyme immunoassays. Results: The mean serum levels of matrix metalloproteinase-9 in the pseudoexfoliation syndrome group was lower than in the control group, p value was 0.112 (p>0.05). The mean serum levels of vascular endothelial growth factor in the pseudoexfoliation syndrome group was lower than in the control group, p value was 0.306 (p>0.05). The mean tissue inhibitor of metalloproteinase-1 and connective tissue growth factor levels in serum samples were higher than in the pseudoexfoliation syndrome group, and p value were respectively 0.491 and 0.283(p>0.05). Conclusion: Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and connective tissue growth factor levels differ in pseudoexfoliation syndrome patients from patients without pseudoexfoliation syndrome in serum. This suppports that extracellular homeostasis is disturbed resulting in accumulation of extracellular matrix. It might be foreseen that development of preventive treatments in the future by regulation of interactions between matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and connective tissue growth factor will inhibit or slow down the progression of pseudoexfoliation syndrome.

Özet

Amaç: Serumda matriks metalloproteinaz doku inhibitörleri-1, matriks metalloproteinaz-9, bağ dokusu büyüme faktörü ve vasküler endotelyal büyüme faktörü düzeylerinin matriks metalloproteinaz-9 psödoeksfolyasyon sendromlu hastalar ile normal hastalar arasında farklı olupolmadığını araştırmak.Gereç ve Yöntem: Çalışmaya psödoeksfoliasyon sendromlu grubundan 50, kontrol grubundan 48 göz dahil edildi. Hastalardan aç karnakoldan 5 mL kan örneği alındı. Kan örneklerinin santrifüjü sonrası elde edilen serum örnekleri derin dondurucuda analiz edilinceye kadar muhafaza edildi. Serum örneklerinde matriks metalloproteinaz doku inhibitörleri-1, matriks metalloproteinaz-9, bağ dokusu büyüme faktörü vevasküler endotelyal büyüme faktörü düzeyleri ELİSA kitleri kullanılarak belirlendi.Bulgular: Serumda matriks metalloproteinaz-9 seviyeleri psödoeksfolyasyon sendromlu grubunda, kontrol grubuna göre azalmış seviyelerde tespit edildi ve p değeri 0,112 olarak saptandı (p>0,05). Serumda vasküler endotelyal büyüme faktörü seviyeleri psödoeksfolyasyon send romlu grubunda kontrol grubuna göre azalmış düzeyde tespit edildi ve p değeri 0,306 olarak saptandı (p>0,05). Serumda metalloproteinaz doku inhibitörleri-1 ve bağ dokusu büyüme faktörü seviyeleri psödoeksfolyasyon sendromlu grubunda, kontrol grubuna göre artmış düzeyde tespit edildi ve p değerleri sırasıyla 0,491 ve 0,283 olarak bulundu (p>0,05). Sonuç: Psödoeksfolyasyon sendromlu olgularda serumda matriks metalloproteinaz, metalloproteinaz doku inhibitörü ve bağ dokusu büyüme faktörü düzeylerinde psödoeksfolyasyon sendromu bulunmayan olgulardan farklılıklar mevcuttur. Bu durum ekstrasellüler matriks homeostazının ekstrasellüler matriksin birikimi yönünde bozulduğunu desteklemektedir. Gelecekte matriks metalloproteinaz-9, metalloproteinaz doku inhibitörleri ve bağ dokusu büyüme faktörü arasındaki ilişkileri düzenleyecek koruyucu tedavilerin geliştirilmesiyle psödoeksfolyasyon sendromlunun gelişiminin engellenebileceği veya yavaşlatılabileceği öngörülebilir

🔖

Cite This Article

TELEK, H. H., YAVRUOĞLU, M. A., ÖZDEMİR, Y. A. (2017). Research of Tissue Inhibitor of Matrix Metalloproteinase-1, Matrix Metalloproteinase-9, Connective Tissue Growth Factor, Vascular Endothelial Growth Factor Levels in Blood in the Eyes of Patients with and Without Pseudoexfoliation Syndrome. MN Oftalmoloji, Cilt: 24 - Sayı: 1, 25–29. https://ajindex.com/articles/295564

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schlötzer-Schrehardt U, Koca MR, Nauman GOH, Volkholz H. Pseudoexfoliation Syndrome. Oculer manifestation of a systemic disease. Arch Ophtalmol 1992;110:1752-56
  2. Streeten BW, Li ZY, Wallace RN, Eagle RC, Keshgegian AA. Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol 1992;110:1757-62
  3. Lindberg JG. Clinical investigations on depigmentation of the pupillary border and translucency of the iris in cases of senile cataract and in normal eyes in elderly persons. Acta Ophthalmol 1989;190:1-96
  4. Ringvold A. Epidemiology of the pseudo-exfoliation syndrome. Acta Ophthalmol Scand 1999;77:371-5
  5. Forsius H, Forsman E, Fellman J, Eriksson AW. Exfoliation syndrome: frequency, gender distrubition and association with climatically induced alterations of the cornea and conjunctiva. Acta Ophthalmol Scand 2002;80:478-84
  6. İrkeç M. Senil psödoeksfoliasyonun epidemiyolojik özellikleri üzerine bir inceleme. Türk Oft Gaz 1979;9:263-68
  7. Yalaz M, Othman I, Nas K, Eroğlu A, Homurlu D, Çikintaş Z, Ashouri A. The frequency of the pseudoexfoliation syndrome in the eastern Mediterranean area of Turkey. Acta Ophthalmol (Copenh) 1992;70:209-13
  8. Schlötzer-Schrehardt U, Dörfler S, Naumann GO. Immunohistoc - hemical localization of basement membrane components in pseudoexfoliation material of the lens capsule. Curr Eye Res 1991; 11:343-55
  9. Ovodenko B, Rostagno A, Neubert TA, Shetty V, Thomas S, Yang A, Liebmann J, Ghiso J, Ritch R. Proteomic analysis of exfoliation deposits. Invest Ophthalmol Vis Sci 1GG7;4B:1447-57
  10. Schlötzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma - New insights from LOXL1 gene associations. Exp Eye Res 2009;88:776-85
  11. Ho S.L, Dogar G.F, Wang J, Crean J, Wu Q.D, Oliver N, Weitz S, Murray A, Cleary P.E, O’Brien C. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br J Ophthalmol 2005;89:169-73
  12. Yoneda K, Nakano M, Mori K, Kinoshita S, Tashiro K. Diseaserelated quantitation of TGF-beta3 in human aqueous humor. Growth Factors 2007;25:160-7
  13. Hammer T, Schlötzer-Schrehardt U, Naumann GO. Unilateral or asymmetric pseudoexfoliation syndrome? An ultrastructural study. Arch Ophthalmol 2001;119:1023-31
  14. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Survey Ophthalmol 2001;45:265-315
  15. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AGP, N